

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

British Thoracic Oncology Group highlighted that KRAS mutation is less common in lung cancer from East and South Asian populations, but nevertheless relevant in all NSCLC populations

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Differences in incidence of a disease cannot be addressed in a technology appraisal. Stakeholders can submit evidence on differing diagnosis timeliness, outcomes and quality of life between different populations.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No

Approved by Associate Director (name): Jasdeep Hayre

Date: 23 April 2021